boceprevir

boceprevir

Victrelis

Pharmacologic class: Hepatitis C NS3/4A protease inhibitor

Therapeutic class: Antiviral agent

Pregnancy risk category X

Action

Binds to the NS3 protease active site serine (S139) through an (alpha)-ketoamide functional group to inhibit viral replication in hepatitis C virus (HCV)-infected host cells

Availability

Capsules: 200 mg

Indications and dosages

➣ Chronic hepatitis C genotype 1 in patients with compensated hepatic disease (including cirrhosis) who are previously untreated or who have failed previous interferon and ribavirin therapy

Adults age 18 and older: 800 mg P.O. t.i.d. (q 7 to 9 hours) in combination with peginterferon alfa and ribavirin; in patients with compensated cirrhosis, give peginterferon alfa and ribavirin for 4 weeks followed by 44 weeks boceprevir 800 mg t.i.d. (q 7 to 9 hours) in combination with peginterferon alfa and ribavirin

➣ Chronic hepatitis C genotype 1 in patients with compensated hepatic disease (without cirrhosis) who are previously untreated or are partial responders or relapsers to interferon and ribavirin therapy

Adults age 18 and older: Initiate therapy with peginterferon alfa and ribavirin for 4 weeks (treatment weeks 1 to 4). Add boceprevir 800 mg P.O. t.i.d. (q 7 to 9 hours) to peginterferon alfa and ribavirin regimen after 4 weeks of treatment. Based on patient's HCV-RNA levels at treatment week 8, treatment week 12, and treatment week 24, use the following response-guided therapy guidelines below to determine duration of treatment.

Complete three-drug regimen at treatment week 28.

Continue all three drugs and finish through treatment week 36; then give peginterferon alfa and ribavirin and finish through treatment week 48.

Complete three-drug regimen at treatment week 36.

Continue all three drugs and finish through treatment week 36; then give peginterferon alfa and ribavirin and finish through treatment week 48.

---

Treatment futility

If the patient has HCV-RNA results of 100 international units/ml or greater at treatment week 12, discontinue three-drug regimen. If the patient has confirmed, detectable HCV-RNA at treatment week 24, discontinue three-drug regimen.

Contraindications

• Contraindications to peginterferon alfa and ribavirin (because boceprevir must be administered with these drugs)

• Concurrent use of drugs that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious or life-threatening events, including cisapride (not available in the United States), alfuzosin, dihydroergotamine, drospirenone, ergonovine, ergotamine, lovastatin, methylergonovine, oral midazolam, pimozide, sildenafil (Revatio) and tadalafil (Adcirca) when used for pulmonary arterial hypertension, simvastatin, and triazolam

• Concurrent use of potent CYP3A4/5 inducers when significantly reduced boceprevir plasma concentrations may be associated with reduced efficacy, including carbamazepine, phenobarbital, phenytoin, rifampin, and St. John's wort

• Pregnancy and in men whose female partners are pregnant

Precautions

Use cautiously in:

• patients with anemia or neutropenia

• patients with decompensated cirrhosis or organ transplant, co-infection with HCV and HIV, or hepatitis B virus

• patients with hepatic or renal impairment (avoid use)

• concurrent use of antidepressants such as trazodone, desipramine, or sedatives-hypnotics such as alprazolam and I.V. midazolam (requires close monitoring and consideration of dosage reduction of these drugs)

• concurrent use of antifungals (dosages of ketoconazole and itraconazole shouldn't exceed 200 mg/day if given with boceprevir)

• concurrent use of colchicine for gout flares, prophylaxis for gout flares, or familial Mediterranean fever (requires dosage reduction)

• concurrent use of rifabutin (not recommended)

• concurrent use of dihydropyridine calcium channel blockers, such as felodipine, nifedipine, and nicardipine (clinical monitoring recommended)

• concurrent use of dexamethasone (avoid use if possible or use with caution if use is necessary)

• concurrent use of inhaled corticosteroids budesonide, fluticasone (avoid use if possible, particularly for extended durations)

• concurrent use of bosentan (monitor patient closely)

• concurrent use of HIV non-nucleoside reverse transcriptase inhibitors such as efavirenz (avoid use)

• concurrent use of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir combinations (not recommended)

• concurrent use of ritonavir

• concurrent use of atorvastatin (requires careful titration; atorvastatin dose not to exceed 20 mg daily)

• concurrent use of salmeterol (not recommended)

• concurrent use of methadone or buprenorphine (clinical monitoring recommended; may require altered methadone or buprenorphine dosage)

• concurrent use of sildenafil, tadalafil, or vardenafil when used for erectile dysfunction (don't exceed recommended reduced dosages of these drugs)

• elderly patients

• breastfeeding patients

• children (safety and efficacy not established).

Administration

• Administer with food (a meal or light snack).

☞ Don't administer boceprevir without peginterferon alfa and ribavirin. Drug must not be used as monotherapy.

• Obtain CBC with WBC differential in all patients before starting drug. Be aware that decreased hemoglobin level or neutrophil count may require a decrease in dosage, interruption, or discontinuation of peginterferon alfa or ribavirin.

• Because this drug is given with ribavirin, ensure that a negative pregnancy test has been obtained immediately before starting therapy.

• Be aware that the Ribavirin Pregnancy Registry is available to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment and for 6 months after treatment cessation.

• Be aware that boceprevir dosage reduction isn't recommended. If the patient has a serious adverse reaction potentially related to peginterferon alfa or ribavirin, the peginterferon alfa or ribavirin dosage should be reduced or discontinued.

Adverse reactions

CNS: fatigue, headache, asthenia, dizziness, insomnia, irritability

GI: nausea, vomiting, diarrhea, dry mouth

Hematologic: anemia, neutropenia

Musculoskeletal: arthralgia

Respiratory: exertional dyspnea

Skin: alopecia, dry skin, rash

Other: chills, dysgeusia, decreased appetite

Interactions

Drug-drug. Alpha₁-adrenoreceptors (alfuzosin): increased alfuzosin concentration, resulting in hypotension

Antiarrhythmics (amiodarone, bepridil [not available in the United States], flecainide, propafenone, quinidine): increased antiarrhythmic concentration with risk of serious or life-threatening adverse events

Anticoagulants (warfarin): altered warfarin concentration

Anticonvulsants (carbamazepine, phenobarbital, phenytoin), antimycobacterials (rifampin): possible loss of virologic response to boceprevir

Antidepressants (desipramine, trazodone): increased trazodone and desipramine plasma concentrations, resulting in increased adverse reactions, such as dizziness, hypotension, and syncope

Antifungals (itraconazole, ketoconazole, posaconazole, voriconazole): increased plasma concentrations of these drugs

Antigout drugs (colchicine): significantly increased colchicine level, resulting in possible fatal toxicity

Anti-infectives (clarithromycin): increased clarithromycin concentration

Antimycobacterials (rifabutin): increased risk of rifabutin exposure and decreased risk of boceprevir exposure

Beta-agonists, inhaled (salmeterol): increased risk of salmeterol-associated CV events

Corticosteroids, inhaled (budesonide, fluticasone): increased budesonide and fluticasone plasma concentrations, resulting in significantly reduced serum cortisol concentration

Corticosteroids, systemic (dexamethasone): decreased boceprevir plasma concentration, with possible loss of boceprevir therapeutic effect

Digoxin: increased digoxin concentration, with risk of toxicity

Dihydropyridine calcium channel blockers (felodipine, nicardipine, nifedipine): increased dihydropyridine calcium channel blocker plasma concentration

Endothelin receptor antagonists (bosentan): increased bosentan concentration

Ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methyler-gonovine): increased risk of acute ergot toxicity characterized by peripheral vasospasm and ischemia of extremities and other tissues

GI motility agents (cisapride, not available in the United States): increased risk of cardiac arrhythmias

HIV non-nucleoside reverse transcriptase inhibitors (efavirenz): decreased boceprevir plasma trough concentration, resulting in loss of boceprevir therapeutic effect

HIV protease inhibitor combinations (atazanavir/ritonavir): reduced steady-state exposure to atazanavir and ritonavir

HIV protease inhibitor combinations (darunavir/ritonavir, lopinavir/ritonavir): reduced steady-state exposure to boceprevir, darunavir, lopinavir, and ritonavir

HIV protease inhibitors (ritonavir): decreased boceprevir concentration HMG-CoA reductase inhibitors (atorvastatin): increased atorvastatin concentration

HMG-CoA reductase inhibitors (lovastatin, simvastatin): increased risk of myopathy, including rhabdomyolysis

Immunosuppressants (cyclosporine, sirolimus, tacrolimus): significantly increased cyclosporine, sirolimus, and tacrolimus plasma concentrations

Neuroleptics (pimozide): increased risk of cardiac arrhythmias

Opioid analgesics (buprenorphine, methadone): possible increased or decreased methadone or buprenorphine plasma concentration

Oral contraceptives (drospirenone): increased risk of hyperkalemia

Oral contraceptives (drospirenone, ethinyl estradiol): increased drospirenone and decreased ethinyl estradiol concentrations (effect on other progestins is unknown but increases in exposure are anticipated)

Phosphodiesterase type 5 enzyme inhibitors (sildenafil, tadalafil) when used for pulmonary arterial hypertension: increased risk of PDE5 inhibitor-associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope

Phosphodiesterase type 5 enzyme inhibitors (sildenafil, tadalafil, vardenafil) when used for erectile dysfunction: increased sildenafil, tadalafil, and vardenafil levels, resulting in increased adverse reactions

Sedative-hypnotics (alprazolam, I.V. midazolam): increased concentrations of alprazolam and midazolam, with risk of respiratory depression or prolonged sedation

Sedative-hypnotics (triazolam, oral midazolam): prolonged or increased sedation or respiratory depression

Drug-diagnostic tests. Hemoglobin, neutrophils, platelets: decreased levels

Drug-food. Any food: enhanced boceprevir exposure

Drug-herbs. St. John's wort: possible loss of virologic response to boceprevir

Patient monitoring

• Continue to monitor CBC with WBC differential at treatment weeks 4, 8, and 12; closely monitor at other times as clinically appropriate.

• Monitor HCV-RNA levels at treatment weeks 4, 8, 12, and 24, at the end of treatment, during treatment follow-up, and at other times as clinically indicated. Be aware that discontinuation of therapy is recommended in all patients with HCV-RNA level of 100 international units/ml or greater at treatment week 12 or confirmed detectable HCV-RNA level at treatment week 24.

• If patient is also receiving antiarrhythmics, bosentan, calcium channel blockers, digoxin, immunosuppressants, or opioid analgesics, monitor therapeutic levels of these drugs.

• Monitor INR closely if patient is receiving warfarin while taking this three-drug combination.

• Closely watch for adverse reactions in patients taking erectile dysfunction drugs while also taking this three-drug combination.

• Closely watch for respiratory depression or prolonged sedation in patients also taking sedatives or hypnotics with this three-drug combination.

Patient teaching

• Tell patient to take drug with food (a meal or light snack).

☞ Advise patient that boceprevir must not be used alone, because of the high probability of resistance without combination anti-HCV therapies.

• Tell patient that if he misses a dose and it's less than 2 hours before the next dose is due, he should skip the missed dose. If he misses a dose and it's 2 or more hours before the next dose is due, he should take the missed dose and then resume the normal dosing schedule.

• Tell patient that laboratory evaluations are required before starting therapy and periodically thereafter.

• Inform female patient that she must have a negative pregnancy test before starting therapy and monthly thereafter during therapy.

• Advise female patient of childbearing age and female partners of male patients to avoid pregnancy during therapy with this three-drug combination by practicing effective contraception with at least two forms of contraceptives during therapy and for 6 months after therapy ends. Tell female patient not to rely on efficacy of systemic hormonal contraceptives during this treatment. Two alternative effective methods of contraception include intrauterine devices and barrier methods.

• Tell female patient of childbearing age that breastfeeding isn't recommended during therapy.

• Instruct patient to tell prescriber about all drugs and herbal products he's taking, because many drugs and some herbs have the potential for serious drug interactions and shouldn't be taken with boceprevir.

• Inform patient that it isn't known how treatment of hepatitis C virus infection affects transmission and that appropriate precautions to prevent transmission of hepatitis C virus should be taken.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, food, and herbs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved

boceprevir

(boe-sep-re-vir) ,

Victrelis

(trade name)

Classification

Therapeutic: antivirals
Pharmacologic: protease inhibitors

Pregnancy Category: B (boceprevir)
Pregnancy Category: X (with peginterferon and ribavirin)

Indications

genetic implication Treatment of chronic hepatitis C (genotype 1) infection in combination with peginterferon alfa and ribavirin in adult patients with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous treatment with interferon and ribavirin, including prior null responders, partial responders, and relapsers.

Action

Acts as an inhibitor of viral protease resulting in a direct antiviral effect; effect is additive with other antivirals.

Therapeutic effects

Decreased progression of hepatic damage and improved virologic response.

Pharmacokinetics

Absorption: Food enhances absorption, bioavailability unknown.

Distribution: Unknown.

Metabolism and Excretion: Mostly metabolized by the liver; metabolites have no antiviral activity; 8% excreted in feces unchanged, 3% excreted in urine unchanged.

Half-life: 3.4 hr.

Time/action profile (blood levels)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	2 hr	7–9 hr

Contraindications/Precautions

Contraindicated in: HypersensitivityConcurrent use with drugs highly dependent on CYP3A4/5 enzyme system for clearance where ↑ levels are associated with serious/life-threatening toxicity;Concurrent use with potent inducers of CYP3A4/5 enzyme systems (may ↓ levels/efficacy); Obstetric: Avoid using in pregnant patients and in male patients whose partners are pregnant (due to concurrent use with ribavirin); Lactation: Avoid breast feeding.

Use Cautiously in: Concurrent infection with HIV or hepatitis B (safety and efficacy not established);Decompensated cirrhosis/organ/co-infection with HIV/hepatitis B (safety and efficacy have not been established); Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

• fatigue (most frequent)
• headache (most frequent)

Dermatologic

• urticaria

Gastrointestinal

• dysgeusia (most frequent)
• nausea (most frequent)
• diarrhea
• vomiting

Hematologic

• anemia (most frequent)
• neutropenia

Miscellaneous

• angioedema (life-threatening)
• hypersensitivity reactions (life-threatening)

Interactions

Drug-Drug interaction

Acts as a strong inhibitor and is partially metabolized by the CYP3A4/5 enzyme system.Concurrent with drugs highly dependent on CYP3A4/5 enzyme system for clearance may result in ↑ levels and serious/life-threatening toxicity and should be avoided, including alfuzosin (may result in hypertension); dihydroergotamine, ergonovine, ergotamine, and methylergonovine (may cause peripheral vasospasm); lovastatin and simvastatin (↑ risk of myopathy); drosperinone (may result in hyperkalemia); sildenafil or tadalafil when used for pulmonary hypertension (↑ risk of visual abnormalities, hypotension, prolonged erection, syncope); triazolam and oralmidazolam (may result in prolonged sedation/respiratory depression).↑ levels of sildenafil, tadalafil, or vardenafil when used for erectile dysfunction; lower doses recommended.↓ levels and contraceptive effectiveness of ethinyl estradiol ; two additional methods of contraception are necessary.May ↑ levels of atorvastatin ; daily dose should not exceed 20 mg.Concurrent use with potent inducers of CYP3A4/5 enzyme system may ↓ levels and efficacy of bocepravir should be avoided, includingcarbamazepine, phenobarbital, and phenytoin.Concurrent use with peginterferon alfa and ribavirin may worsen expected neutropenia.May ↑ levels and risk of adverse cardiovascular reactions with amiodarone, flecainide, propafenone, quinidine, or digoxin ; undertake concurrent use with caution; drug level monitoring recommended.May alter response to warfarin ; INR monitoring recommended.May ↑ levels of itraconazole, ketoconazole, posaconazole, or voriconazole ; doses of ketoconazole or itraconazole should not exceed 200 mg/day.May ↑ levels of desipramine or trazodone and result in dizziness, hypotension or syncope, consider lower doses.May ↓ levels of escitalopram ↑ levels and risk of toxicity with colchicine ; avoid concurrent use in hepatic/renal impairment, dosage reduction recommended for others.↑ rifabutin levels; rifabutin may ↓ bocepravir levels; concurrent use should be avoided.May ↑ levels and risk of adverse cardiovascular reactions with felodipine, nifedipine, or nicardipine ; caution and clinical monitoring recommended.Concurrent use with dexamethasone may ↓ levels and effectiveness; avoid if possible.May ↑ blood levels of inhaledbudenoside or fluticasone resulting in ↓ cortisol levels; avoid extended concurrent use.May ↑ prednisone, bosentan, digoxin, and rilpivirine levelsConcurrent use with salmeterol may ↑ risk of adverse cardiovascular events.May alter levels of methadone or buprenorphine ; monitor effects.May ↑ levels and risk of toxicity with, cyclosporine, sirolimus, or tacrolimus ; dose ↓ and monitoring levels is required.Efavirenz may ↓ levels; avoid concurrent use.May ↓ levels of atazanavir/ritonavir ; concurrent use not recommendedConcurrent use with darunavir/ritonavir may ↓ levels of darunavir, ritonavir, and boceprevir ; concurrent use not recommendedConcurrent use with lopinavir/ritonavir may ↓ levels of lopinavir, ritonavir, and boceprevir ; concurrent use not recommendedRitonavir may ↓ levelsMay ↑ risk of myopathy with atorvastatin and pravastatin ; do not exceed atorvastatin dose of 40 mg/day.May ↓ etravirine levelsConcurrent use of St. John's wort (hypericum perforatum) ↑ metabolism and may ↓ effectiveness and should be avoided.

Route/Dosage

Oral (Adults) 800 mg three times daily.

Availability

Capsules: 200 mg

Nursing implications

Nursing assessment

• Monitor symptoms of hepatitis during therapy.
• Monitor patient for signs of infection (vital signs, sputum, WBC) during therapy. Peginterferon alfa-2a should be discontinued in cases of severe infection, and antibiotic therapy instituted.
• Monitor for signs and symptoms of hypersensitivity reactions (angioedema, urticaria). Discontinue boceprevir and institute therapy as needed.
• Assess for rash periodically during therapy. Discontinue therapy if rash becomes severe.
• Lab Test Considerations: Monitor CBC with differential prior to and at prior to starting therapy and at Treatment Weeks 2, 4, 8, and 12, and as clinically appropriate. If hemoglobin is <10 g/dL, decrease or interrupt ribavirin. If hemoglobin is <8.5 g/dL discontinue ribavirin. Decrease in neutrophil count may require dose reduction or discontinuation of peginterferon alfa or ribavirin.
  • Monitor HCV-RNA levels at Treatment Weeks 4, 8, 12, and 24, at end of treatment, during treatment follow-up, and when clinically indicated to determine effectiveness of therapy.

Potential Nursing Diagnoses

Risk for infection (Indications,  Side Effects)

Implementation

• Therapy begins with peginterferon alfa and ribavirin for 4 wks, then boceprevir is added; do not use as monotherapy.
• Oral: Administer 3 times daily, every 7–9 hrs, with a meal or light snack.

Patient/Family Teaching

• Instruct patient to take boceprevir as directed. If a dose is missed and it is less than 2 hrs before next dose, skip dose; if more than 2 hrs before next dose, take dose and resume normal dosing schedule.
• Inform patient that boceprevir may not reduce the risk of transmission of HCV to others; precautions should be taken.
• Instruct patient to notify health care professional immediately if signs and symptoms of hypersensitivity reactions or skin reactions with symptoms (flu-like symptoms, fever, muscle aches, conjunctivitis, blisters, mouth sores, swelling of face, tiredness) occur.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications, especially St. John's Wort.
• Inform female patients of the importance of simultaneously using two reliable forms of contraception, unless abstinence is the chosen method, during therapy and for 6 mo post-therapy. Advise pregnant women and men whose female partners are pregnant to avoid this therapy due to birth defects and fetal death with ribavirin. Encourage pregnant patients or partners to register with Ribavirin Pregnancy Registry by calling 1-800-593-2214.

Evaluation/Desired Outcomes

• Decreased progression of hepatic damage and improved virologic response.
  • Therapy is discontinued if HCV-RNA levels are ≥100 IU/mL at Treatment Week 12 or confirmed detectable HCV-RNA levels at Treatment Week 24.

Drug Guide, © 2015 Farlex and Partners